Shares of Abiomed Inc. (NSDQ:ABMD) ticked up 1.6 percent today on data showing that it helps high-risk patients during emergency heart treatment.
Data from the Protect II clinical trial of its Impella 2.5 heart pump, presented today at the annual meeting of the American College of Cardiology in New Orleans, showed that the device "provides superb hemodynamic support during high-risk interventions," according to lead investigator Dr. William O’Neill of the University of Miami.